FDA panel votes 8-5 that breo ellipta helps reduce lung disease severity (THRX) (GSK)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Theravance (THRX) Pops on Resumption; Receives Positive FA Panel Vote on Breo
April 17, 2013 4:28 PM EDTTheravance, Inc. (Nasdaq: THRX) shares are popping late following the restart to trading. The rise stems from a positive FDA panel vote on Breo Ellipta for CPOD.
The release is below:
GlaxoSmithKline plc (NYSE: GSK) and Theravance announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO" ELLIPTA" as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic... More
FDA panel votes 10-3 the breo ellipta safety has been demonstrated (THRX) (GSK)
April 17, 2013 2:18 PM EDTFDA panel votes 10-3 the breo ellipta safety has been demonstrated. The drug is being developed by Theravance, Inc. (NASDAQ: THRX) and Glaxo (NYSE: GSK).... More
Theravance (THRX) Halted Into FDA Advisory Committee Breo Ellipta Meeting
April 17, 2013 7:08 AM EDTTheravance, Inc. (Nasdaq: THRX) announced that NASDAQ halted trading of Theravance common stock this morning, April 17, 2013. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to discuss the new drug application (NDA) 204275, for fluticasone furoate (FF) and... More
Theravance (THRX) halted with news pending
April 17, 2013 7:00 AM EDTTheravance, Inc. (NASDAQ: THRX) halted with news pending.... More
Theravance (THRX) Trades Strong; Breo Briefing Docs Posted Ahead of Meeting (GSK)
April 15, 2013 11:00 AM EDTTheravance (Nasdaq: THRX) is strongly positive Monday into an upcoming FDA advisory meeting for proposed chronic obstructive pulmonary disease (COPD) treatment Breo Ellipta, which is being co-developed with GlaxoSmithKline (NYSE: GSK). The meeting is scheduled to take place on Wednesday, April... More
